Telix Pharmaceuticals Limited
HealthcareNASDAQ:TLX · NASDAQ Global Select
+$0.11 today
Vol 0.38M · Avg 0.21M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$10.7M -121.4% | $49.9M +858.0% | $5.2M +105.0% | -$104.1M -29.3% | -$80.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $32.7M +307.4% | $8.0M +18.9% | $6.7M +25.4% | $5.4M +4.0% | $5.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $19.7M +123.8% | $8.8M +8.3% | $8.1M +513.8% | $1.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$67.8M +31.4% | -$98.8M -71.8% | -$57.5M -100.9% | -$28.6M -286.2% | -$7.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$30.7M +46.2% | -$57.1M -108.5% | -$27.4M -37.4% | -$19.9M -177.2% | -$7.2M | $592.6M | $1.3B | $626.2M |
| Inventory | -$11.5M -253.7% | -$3.2M +66.4% | -$9.6M -91.8% | -$5.0M -78.1% | -$2.8M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $43.5M | $0 | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$69.1M -79.5% | -$38.5M -87.7% | -$20.5M -456.6% | -$3.7M -242.0% | $2.6M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $19.9M -69.0% | $64.3M +5.9% | $60.7M +9.8% | $55.3M +150.0% | $22.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$25.9M -160.3% | $43.0M +80.2% | $23.9M +137.3% | -$64.0M -7.8% | -$59.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$56.9M -297.0% | -$14.3M -48.0% | -$9.7M -37.5% | -$7.0M -425.6% | -$1.3M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$330.9M -853.8% | -$34.7M -2237.9% | -$1.5M -52.5% | -$973.0K | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.3M | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$12.5M +85.4% | -$86.2M -501.4% | -$14.3M -59.4% | -$9.0M -547.9% | -$1.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$428.8M -217.2% | -$135.2M -430.3% | -$25.5M -50.0% | -$17.0M -523.5% | -$2.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$434.9K -100.1% | $652.8M +18372.2% | $3.5M +103.5% | $1.7M +285.6% | -$936.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.7M | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$7.9M +43.4% | -$13.9M -308.7% | $6.7M -96.2% | $173.2M +4480.2% | $3.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$5.6M -100.9% | $638.9M +6172.6% | $10.2M -94.2% | $175.0M +6047.6% | $2.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $13.9M -65.4% | $40.3M +2510.6% | -$1.7M -659.5% | $299.0K -90.9% | $3.3M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$446.4M -176.0% | $587.1M +8399.0% | $6.9M -92.7% | $94.3M +268.7% | -$55.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$82.8M -388.4% | $28.7M +102.1% | $14.2M +120.0% | -$71.0M -17.0% | -$60.7M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Celcuity Inc.
NASDAQ:CELC
$4.32B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
SEC Filings
Recent regulatory filings
No filings found.
Does TLX generate free cash flow?
Telix Pharmaceuticals Limited (TLX) generated -$82,795,327.00 of free cash flow in fiscal 2025.
How much operating cash flow does TLX produce?
Operating cash flow was -$25,933,808.00, before capital expenditures of $56.86M.
Explore More
Continue the stock analysis
Jump to another research area for this company.